Table 2 Characteristics of the 23 patients with deteriorating lung function*
Parameter (n) | Time of deterioration month | Baseline | Deterioration | Extent of deterioration | |
|---|---|---|---|---|---|
Absolute value† | Absolute value† | P value‡ | |||
% of predicted | % | ||||
FVC (n = 6) | 14.3 (8 · 4–23) | 3350 (3100–3810) | 2745 (2330–2950) | −665 (−770; −590) | 0.03 |
98 (85–112) | 80 (64–94) | −20 (−22.6; −16.2) | |||
FEV1 (n = 13) | 12.8 (5.8–18.2) | 2540 (2390–3300) | 1990 (1740–2770) | −460 (−530; −400) | <0.001 |
90.1 (80; 96 · 0) | 77.2 (67 · 9; 78 · 7) | −16.7 (−18.8; −15.8) | |||
DLCO (n = 14) | 11.7 (6.2–17.6) | 6 (4.7-6.5) | 4.82 (3.6-5.31) | −1.17 (−1 · 4; −0.95) | <0.001 |
64.3 (57–72) | 50 (44–60) | −17.8 (−19 · 2; −16 · 3) | |||
6-minute walk distance, m | 505 (480–547) | 529 (471–564) | 0 (−36; +31.5) | 0.71 | |
PaO2, mm Hg | 79 (75–88) | 86 (79–90) | −1 (−6; +12) | 0.38 | |
SGRQ score§ | 21.8 (10 · 8–43 · 5) | 16.1 (7.3–28.7) | −3.2 (−11.2; +2.1) | 0.12 | |
HRCT nodular score║ | 7.5 (6–10) | 6.5 (5–10) | 0 (0–0) | 0.69 | |
HRCT cystic score | 6.5 (5–11) | 7 (4–12) | 0 (0–2) | 0.18 | |